Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
Novartis maintains growth momentum, confirms FY 2022 guidance
Top 2022 priorities on track
1
Successful launches: Leqvio (laying the foundation), Kesimpta, Pluvicto, Scemblix
2
Maintain growth momentum: YC CE AZ K KL
3
Progress pipeline: Multiple assets with significant sales potential, approval by 2026, on track
4
New focused strategy: Spin Sandoz¹; “pure-play" IM; 5 core TAs²; 2+3 technology platforms³
5
Deliver returns: Continue productivity initiatives. New organizational model being implemented
6
Strengthen foundations: Culture to drive performance, data science to drive value, ESG leadership
IM - Innovative Medicines TAS Therapeutic areas 1. Intention to separate Sandoz via 100% spin-off; completion planned H2 2023. 2. Cardiovascular, immunology, neuroscience, solid tumors, hematology. 3. Two established
(chemistry and biotherapeutics), three emerging (gene & cell therapy, radioligand therapy, and XRNA).
29 Investor Relations | Q3 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation